Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Monopar Therapeutics Inc. (MNPR) had Return on Tangible Equity of -4.06% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-5.31M |
|
-- |
|
-- |
|
$6.64M |
|
$-6.64M |
|
$1.33M |
|
$-5.31M |
|
$-5.31M |
|
$-5.31M |
|
$-5.31M |
|
$-5.31M |
|
$-5.31M |
|
$-6.64M |
|
$-7.35M |
|
8.54M |
|
8.54M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$134.76M |
|
-- |
|
$0.22M |
|
$134.98M |
|
$4.02M |
|
-- |
|
$0.11M |
|
$4.12M |
|
$130.85M |
|
$130.85M |
|
$130.85M |
|
6.71M |
|
| Cash Flow Statement Financials | |
$-6.72M |
|
$-1.47M |
|
$-0.85M |
|
$61.83M |
|
$52.76M |
|
$-9.08M |
|
$3.12M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
33.56 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.72M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-4.06% |
|
|
Return on Tangible Equity |
-4.06% |
-3.94% |
|
-4.06% |
|
$19.50 |
|
$-0.79 |
|
$-0.79 |
|